Although PARPi have achieved great success in treating patients with BRCA1/2 mutated cancers, the current application of PARPi still faces some challenges, especially in improving the efficacy of PARPi in BRCA1/2 wild-type cancer patients and overcoming acquired resistance to PARPi. The gene discussed is BRCA1; the disease is cancer.